Sage Q1: $6.2M ZURZUVAE revenue, fails Phase 2 Parkinson's study; net loss $108.5M

Sage Therapeutics, Inc.

2024-Q1 EPS reported -$1.80 revenue$7,902,000

ZURZUVAE collaboration revenue $6.2M (50% of Biogen net); 700+ prescriptions shipped in Q1.
Phase 2 PRECEDENT (dalzanemdor in Parkinson's MCI) missed primary endpoint; no further development planned.
Cash, equivalents, securities $717M at Mar 31, 2024, down from $753M at Dec 31, 2023.
Net loss $108.5M vs $146.8M YoY; R&D expenses $71.7M, SG&A $52.6M, both down YoY.
Payor coverage >65% of commercial lives for ZURZUVAE; guidance: cash into 2026, expenses down in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Sage Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: revenue $6.2 million in ZURZUVAE collaboration revenue.

Period: the first quarter ended March 31, 2024
Revenue: $6.2 million in ZURZUVAE collaboration revenue
Result: reported results

Exact text from the filing

filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress Achieved $6.2 million in ZURZUVAE TM (zuranolone) collaboration revenue during the first quarter of 2024, representing 50% of the net revenues reported by Biogen Encouraging initial demand for

View on SEC.gov

492 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001193125-24-111481

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.